Mobile

Study to find out whether “Evacetrapib” can help patients who suffer from blockages in the blood vessels to their heart, brain, or legs who are at high risk for having a heart attack, stroke or may ev...

Update Il y a 4 ans
Reference: EUCTR2012-000061-21

Study to find out whether “Evacetrapib” can help patients who suffer from blockages in the blood vessels to their heart, brain, or legs who are at high risk for having a heart attack, stroke or may even die from the disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objective of this study is to test the hypothesis that evacetrapib 130 mg daily, in comparison to placebo, reduces the incidence of the composite endpoint of cardiovascular (CV) death, mycocardial infarction (MI), storke, coronary revascularization, or hospitalization for unstable angina (UA) in high-risk vascular disease (HRVD) patients.

Inclusion criteria

  • High Risk Vascular Disease (HRVD)

Links